Stroke Patients Given Epoetin In Trial Had Higher Mortality Rate, FDA Warns
This article was originally published in The Pink Sheet Daily
Executive Summary
The off-label use is not expected to have commercial impact, analyst says.
You may also be interested in...
The Future Of ESAs – Is It All CKD Now?
Takeda and Affymax revise Hematide program to stop development for chemotherapy-induced anemia and focus on anemia related to chronic kidney disease.
FDA Flexes New FDAAA Muscle With ESA Safety Labeling - And May Help Tone Up Amgen’s Franchise
Agency uses new authority to mandate label changes by Amgen and J&J in areas where negotiations were unsuccessful.
Pharma's Reform Bounce: How Big a Bounce Will $80 Bil. Buy?
Drug manufacturers made a pledge to contribute $80 bil. in a mix of savings and revenue-raising initiatives to help fund health reform. In return, they could see a wide range of new business depending on how you look at the numbers.